A Phase II trial investigating crenolanib plus salvage chemotherapy in R/R FLT3-mutated AML
Автор: VJHemOnc – Video Journal of Hematology & HemOnc
Загружено: 2025-12-08
Просмотров: 20
Описание:
Eunice Wang, MD, Roswell Park Comprehensive Cancer Center, Buffalo, NY,
discusses the results of a randomized Phase II study (NCT03250338) investigating the efficacy of crenolanib, a new generation FLT3 inhibitor, in patients with relapsed/refractory (R/R) FLT3-mutated acute myeloid leukemia (AML). Dr Wang highlights that the addition of crenolanib to standard intensive salvage chemotherapy resulted in improved responses. This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Повторяем попытку...
Доступные форматы для скачивания:
Скачать видео
-
Информация по загрузке:
